glp 1 agonist liraglutide Des-Gly4)-Liraglutide Cardiovascular Protection with a Long-Acting
Description
doi: 10.1210/clinem/dgab408 [DOI] [PubMed] [Google Scholar] 201

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Rodriguez PJ, Zhang V, Gratzl S et al

A large study that compared tirzepatide to semaglutide showed that in non-diabetic, overweight adults, the risk of gastroparesis was much higher in semaglutide recipients compared to tirzepatide
